New treatment for familial polycystic kidney disease

An important breakthrough has been achieved in the treatment of autosomal-dominant polycystic kidney disease (ADPKD), also referred to as familial polycystic kidney disease. ADPKD is a hereditary disease that becomes symptomatic in adult age, leading to progressive renal failure.

Since August 2015, the medication Tolvaptan has been approved for treatment of ADPKD. It reduces both cyst growth and slows down the loss of kidney function. CECAD scientist and congress president of the DGfN annual conference, Prof. Dr. Thomas Benzing, stated: "Tolvaptan inhibits progression, however, it is not yet an option for all patients with polycystic kidney disease. Therefore, research on targeted treatments has to continue.“
The Institute II for Internal Medicine of the University Hospital Cologne can provide patients suffering from this disease with further information regarding the new treatment. Please click here.

Please find detailed information in the "KrankenPflege-Journal“ article, released September 15, 2015. Or listen to the radio interview with Prof. Benzing on "Deutschlandfunk", also released September 15.